Tillkännagivande • Nov 07
Blonder Tongue Announces IP Failover Feature Added to NXG Video Delivery System Blonder Tongue Laboratories, Inc. announced an important addition to the best-selling NXG Video Delivery Platform. The NXG-IP input module will now support an input path failover for up to two Gigabit Ethernet input feeds. If an operator provides two inbound network routes containing identical SPTS programming, the NXG-IP can now automatically failover from the primary feed to the secondary feed if a loss of data is detected. This failover is performed on a per-program basis, so this mechanism can protect against both path loss, i.e., fiber/infrastructure damage and receiver failure. This new addition to the NXG-IP module will be available as a field-upgradable firmware, with the update available now. The Blonder TongueNXG Video Delivery Platform, available in 3 and 5-RU rack chassis, offers solutions that are highly customizable, module-based IP digital video processing platforms designed for delivering next generation video services on any generation of coax, ethernet, or fiber-optic wiring - without the need for replacing existing infrastructure. Tillkännagivande • Feb 15
Blonder Tongue Laboratories, Inc. Announces the Retirement of Stephen K. Necessary from the Board On February 7, 2023, Stephen K. Necessary notified the Nominating and Corporate Governance Committee of the board of directors (the Board") of Blonder Tongue Laboratories, Inc. (the Company") that he will retire from the Board immediately following the Company's 2023 Annual Meeting of Stockholders, scheduled to be held on May 24, 2023. Mr. Necessary has served as a director of the Company since 2018. Tillkännagivande • Oct 29
Blonder Tongue Laboratories, Inc. to Report Q3, 2022 Results on Nov 04, 2022 Blonder Tongue Laboratories, Inc. announced that they will report Q3, 2022 results at 9:30 AM, US Eastern Standard Time on Nov 04, 2022 Tillkännagivande • Oct 27
Blonder Tongue Laboratories Announces Product Standardization with Tier One Broadband Cable Operator Blonder Tongue Laboratories, Inc. announced that the Drake PEG PLUS Advanced Video Encoder (the "Drake PEG PLUS") has been standardized by a North American-based tier one broadband cable operator for providing local content contribution and backhaul to their national IP video operations center. The high reliability of the Drake PEG PLUS, its superb video quality, effective remote management, dual encode, native ZIXI support, and additional unique features were the major factors in the tier one operator's recent decision. The Drake PEG PLUS is a professional stand-alone digital video encoder, and recently incorporated ZIXI error correction and security technology at no additional cost. This allows local contribution video and audio content to be reliably and securely streamed over an unmanaged network, including the public internet, allowing telco, cable, and fiber optic service providers to backhaul and centralize their content distribution without the need to lease or install private lines. The ZIXI protocol provides professional broadcasters, sports networks, and service providers a mechanism to adapt the public internet using standard IP protocols, to ingest and transport broadcast quality video with high reliability and high quality of service. The Drake PEG PLUS also uniquely offers two separately encoded versions of a common input in either MPEG-2 or MPEG-4/H.264 HD or SD formats concurrently. The Drake PEG PLUS features selectable HD-SDI PCM-embedded audio, or analog left and right baseband audio and video. Audio compression can be Dolby® Digital, MPEG1-Layer 2 stereo, or AAC stereo. Direct fiber optic or ethernet connectivity is supported through a single SFP port and SFP module or RJ45 port. Tillkännagivande • Aug 06
Blonder Tongue Laboratories, Inc. to Report Q2, 2022 Results on Aug 15, 2022 Blonder Tongue Laboratories, Inc. announced that they will report Q2, 2022 results at 9:30 AM, US Eastern Standard Time on Aug 15, 2022 Tillkännagivande • Jun 30
Blonder Tongue Laboratories, Inc.(OTCPK:BDRL) dropped from S&P TMI Index Blonder Tongue Laboratories, Inc.(OTCPK:BDRL) dropped from S&P TMI Index Tillkännagivande • Jun 25
NYSE American to Suspend Trading Immediately in Blonder Tongue Laboratories NYSE American LLC (“NYSE American” or the “Exchange”) announced that the staff of NYSE Regulation has now determined to immediately suspend trading in the common stock of Blonder Tongue Laboratories, Inc. (the “Company”) - ticker symbol BDR - from the Exchange. This follows the Exchange’s December 10, 2021 announcement initiating delisting proceedings. The Company had requested a review of the NYSE American delisting determination before a Committee of the Board of Directors of the Exchange. On June 24, 2022, the Company provided formal notification of its intention to withdraw its request for such review. Accordingly, the NYSE American will now suspend trading in the common stock and will file a delisting application with the Securities and Exchange Commission. Tillkännagivande • Jun 07
Blonder Tongue Laboratories, Inc. Announces Furloughing Ronald V. Alterio, the Senior Vice President-Engineering and Chief Technology Officer In an effort to reduce its cash use, Blonder Tongue Laboratories, Inc. is furloughing Ronald V. Alterio, the Company’s Senior Vice President-Engineering and Chief Technology Officer, effective June 6, 2022, for approximately 60 days. In his absence, the Company believes that it has sufficient engineering staff to ensure that there will be no disruption in policies, procedures or practices relating to the Company’s engineering and research and development activities or in connection with the manufacture and shipping of its products. Tillkännagivande • May 18
Blonder Tongue Laboratories, Inc. Announces Resignation of Anthony Bruno as BOD, Effective from May 25, 2022 On May 13, 2022, Anthony Bruno, a member of the board of directors of Blonder Tongue Laboratories, Inc. (the “Company”), informed the Company that he will retire from the board of directors effective immediately following the Company's 2022 Annual Meeting of Stockholders, scheduled to be held on May 25, 2022. Mr. Bruno has served as a director since 2008. Tillkännagivande • Feb 11
Blonder Tongue Laboratories, Inc., Annual General Meeting, May 25, 2022 Blonder Tongue Laboratories, Inc., Annual General Meeting, May 25, 2022, at 10:00 US Eastern Standard Time. Location: One Jake Brown Road Old Bridge New Jersey United States Tillkännagivande • Jan 29
Blonder Tongue Laboratories, Inc. Announces Retirement of James H. Williams as Member of the Board of Director Blonder Tongue Laboratories, Inc. announced on January 25, 2022, James H. Williams, a member of the board of directors, informed the Company that he will retire from the board of directors and will not stand for reelection at the Company’s 2022 Annual Meeting of Stockholders. His retirement will become effective immediately following the Annual Meeting. Mr. Williams has served as a director since February 2015 and also previously served as a director from November 1988 to May 2006, including serving as Chairman from November 1988 until November 1994. Tillkännagivande • Dec 13
NYSE American to Commence Delisting Proceedings Against Blonder Tongue Laboratories NYSE American LLC announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Blonder Tongue Laboratories, Inc. from the Exchange. NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1009(a) of the NYSE American Company Guide (the “Company Guide”) as the Company was unable to demonstrate that it had regained compliance with all of Sections 1003(a)(i), (ii) and (iii) of the Company Guide by the end of the maximum 18-month compliance plan period, which expired on December 10, 2021. The Company has a right to a review of staff’s determination to delist the common stock by a committee of the Board of Directors of the Exchange (the “Committee”). Following such appeal, a decision by the Committee will be made and announced by NYSE Regulation regarding either proceeding with suspension and delisting or continued trading in the Company’s common stock. If the Company does not appeal this determination, NYSE American will announce the date that trading will be suspended. The filing of an application with the Securities and Exchange Commission to delist the common stock is pending completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision. Executive Departure • Dec 02
Independent Director Rick Briggs has left the company On the 24th of November, Rick Briggs' tenure as Independent Director ended after 1.3 years in the role. As of September 2021, Rick still personally held only 25.11k shares (US$29k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 2.58 years. Recent Insider Transactions • Nov 02
Independent Director recently sold US$102k worth of stock On the 29th of October, James Williams sold around 91k shares on-market at roughly US$1.12 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$612k more than they bought in the last 12 months. Reported Earnings • Oct 25
Third quarter 2021 earnings released: US$0.016 loss per share (vs US$0.18 loss in 3Q 2020) The company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were flat. Third quarter 2021 results: Revenue: US$4.17m (flat on 3Q 2020). Net loss: US$201.0k (loss narrowed 89% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Reported Earnings • Aug 13
Second quarter 2021 earnings released: EPS US$0.14 (vs US$0.12 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$4.34m (up 13% from 2Q 2020). Net income: US$1.63m (up US$2.82m from 2Q 2020). Profit margin: 38% (up from net loss in 2Q 2020). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance. Recent Insider Transactions • Jul 10
Director recently sold US$74k worth of stock On the 8th of July, Robert Palle sold around 50k shares on-market at roughly US$1.48 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$371k more than they bought in the last 12 months. Reported Earnings • May 16
First quarter 2021 earnings released: US$0.036 loss per share (vs US$0.21 loss in 1Q 2020) The company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2021 results: Revenue: US$3.25m (down 20% from 1Q 2020). Net loss: US$414.0k (loss narrowed 80% from 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance. Reported Earnings • Mar 27
Full year 2020 earnings released: US$0.76 loss per share (vs US$0.077 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: US$16.4m (down 18% from FY 2019). Net loss: US$7.47m (loss widened US$6.73m from FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 111 percentage points per year, which is a significant difference in performance. Recent Insider Transactions • Mar 19
Independent Director recently sold US$77k worth of stock On the 17th of March, Anthony Bruno sold around 52k shares on-market at roughly US$1.48 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$129k more than they bought in the last 12 months. Tillkännagivande • Mar 18
Blonder Tongue Laboratories, Inc. announced that it has received $0.6 million in funding On March 17, 2021, Blonder Tongue Laboratories, Inc. (AMEX:BDR) closed the transaction. The transaction included participation from two investors. Is New 90 Day High Low • Feb 09
New 90-day high: US$1.85 The company is up 89% from its price of US$0.98 on 10 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Communications industry, which is up 28% over the same period. Recent Insider Transactions • Dec 23
MD of Strategic Accounts & Director recently sold US$52k worth of stock On the 18th of December, Robert Pallé sold around 40k shares on-market at roughly US$1.30 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Tillkännagivande • Dec 13
Blonder Tongue Laboratories Receives Non-Compliance Letter from NYSE American Blonder Tongue Laboratories, Inc. announced that it has received notice from NYSE American LLC (“NYSE American”) that it is not in compliance with the continued listing standard set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”). That section applies if a listed company has stockholders’ equity of less than $4 million and has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Company reported stockholders’ equity of $2,614,000 as of September 30, 2020, the end of its most recent fiscal quarter, and has had losses from continuing operations and/or net losses in each of its five most recent fiscal years including the fiscal year ended December 31, 2019. This notice is in addition to the notice the Company received from NYSE American on June 10, 2020, notifying the Company that it was not in compliance with the continued listing standard set forth in Section 1003(a)(iii) of the Company Guide because the Company reported stockholders’ equity of less than $6 million as of March 31, 2020 and reported losses from continuing operations and/or net losses in each of its five most recent fiscal years ended December 31, 2019. The Company submitted a detailed financial plan to regain compliance with the listing standard set forth in Section 1003(a)(iii) to NYSE American and on August 27, 2020, the Company received notice that its plan had been accepted and that the Company had been granted a plan period through December 10, 2021. The December 10, 2021 deadline will also apply to the notice regarding noncompliance with Section 1003(a)(ii) of the Company Guide. As a result, the Company must be in compliance with Section 1003(a)(ii) and Section 1003(a)(iii) by that deadline. Further, the proposed plan submitted by the Company and approved by the NYSE American on August 27, 2020 included an expectation and anticipation of stockholder’s equity falling below the $4 million threshold before improving to compliance before the December 10, 2021 deadline. The listing of the Company’s common stock on NYSE American is being continued during the plan period pursuant to an extension. During the plan period the Company will be subject to periodic review by NYSE Regulation staff, including quarterly monitoring, to determine if the Company is making progress consistent with the plan. If the Company is not in compliance with the continued listing standards by December 10, 2021, or if NYSE Regulation determines that the Company is not making sufficient progress consistent with the plan, delisting proceedings will may be instituted against the Company, as appropriate. Is New 90 Day High Low • Dec 08
New 90-day high: US$1.75 The company is up 109% from its price of US$0.84 on 09 September 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Communications industry, which is up 12% over the same period. Reported Earnings • Nov 15
Third quarter 2020 earnings released: US$0.18 loss per share The company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: US$4.17m (down 21% from 3Q 2019). Net loss: US$1.79m (loss widened 34% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 77% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Oct 13
New 90-day high: US$1.50 The company is up 111% from its price of US$0.71 on 15 July 2020. The American market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Communications industry, which is down 10.0% over the same period. Tillkännagivande • Sep 04
NYSE Accepts Compliance Plan of Blonder Tongue Laboratories, Inc Blonder Tongue Laboratories, Inc. announced that it has received notice from NYSE Regulation that it has accepted the Company's plan to regain compliance with the NYSE American LLC ("NYSE American") continuing listing standard provided in Section 1003(a)(iii) of the NYSE American Company Guide ("Section 1003(a)(iii)"). As previously disclosed, on June 10, 2020, the Company received notification (the "Non-Compliance Notice") from NYSE American that the Company was not in compliance with Section 1003(a)(iii). That section applies if the reported stockholders' equity of the listed company is less than $6 million and the listed company has reported losses from continuing operations and/or net losses in its five most recent fiscal years. The Non-Compliance Notice indicated that the Company reported stockholders' equity of $5.4 million as of March 31, 2020 and reported losses from continuing operations and/or net losses in each of its five most recent fiscal years ended December 31, 2019, resulting in the Company failing to comply with the continued listing standard. As a result, the Company was required to submit a plan to NYSE American by July 10, 2020 addressing how the Company intends to regain compliance with Section 1003(a)(iii) by December 10, 2021. In accordance with NYSE American's policies and procedures, the Company submitted its plan of compliance prior to the deadline. On August 27, 2020, the Company received notice from NYSE Regulation that it had accepted the Company's plan to regain compliance with Section 1003(a)(iii) and granted a plan period through December 10, 2021. The listing of the Company's common stock on NYSE American is being continued during the plan period pursuant to an extension. In addition, during the plan period the Company will be subject to periodic review by NYSE Regulation staff, including quarterly monitoring, to determine if it is making progress consistent with the plan. If the Company is not in compliance with the continued listing standards by December 10, 2021, or if the Company does not make sufficient progress consistent with its plan, NYSE Regulation staff will initiate delisting proceedings as appropriate. If that were to occur, the Company would have the right to appeal any delisting determination. The Company can provide no assurances that it will be able to make progress with respect to its plan that NYSE Regulation will determine to be satisfactory, that it will regain compliance with Section 1003(a)(iii) on or before the expiration of the plan period, or that developments and events occurring subsequent to the Company's formulation of the compliance plan or its acceptance by NYSE Regulation will not adversely affect the Company's ability to make sufficient progress and/or regain compliance with Section 1003(a)(iii) on or before the expiration of the plan period or result in the Company's failure to be in compliance with other NYSE American continued listing standards. Receipt of the notice from NYSE Regulation accepting the Company's plan does not affect the Company's business, operations or reporting requirements with the Securities and Exchange Commission, and the Company's common stock will continue to be listed and traded on NYSE American, subject to periodic review by NYSE Regulation. Tillkännagivande • Jul 31
Blonder Tongue Laboratories, Inc. to Report Q2, 2020 Results on Aug 07, 2020 Blonder Tongue Laboratories, Inc. announced that they will report Q2, 2020 results at 9:00 AM, Eastern Standard Time on Aug 07, 2020 Tillkännagivande • Jun 18
Blonder Tongue Announces Receipt of Noncompliance Notice from NYSE American Blonder Tongue Laboratories, Inc. (NYSE American: BDR) announced that it has received notice from NYSE American LLC ("NYSE American") that it is not in compliance with the continued listing standard set forth in Section 1003(a)(iii) of the NYSE American Company Guide (the "Company Guide"). That section applies if a listed company has stockholders' equity of less than $6 million and has reported losses from continuing operations and/or net losses in its five most recent fiscal years. The Company reported stockholders' equity of $5.4 million as of March 31, 2020, the end of its first fiscal quarter of 2020, and has had losses from continuing operations and/or net losses in each of its five most recent fiscal years including the fiscal year ended December 31, 2019. As a result, the Company has become subject to the procedures and requirements of Section 1009 of the Company Guide and must submit a plan to NYSE American by July 10, 2020 addressing how the Company intends to regain compliance with Section 1003(a)(iii) by December 10, 2021.